Rosa Baumgartinger

Rosa Baumgartinger

Auto-generated profile, based on publicly available information

Rosa Baumgartinger

Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
AGAndreas Gollner
Andreas Gollner
DRDorothea Rudolph
Dorothea Rudolph
UWUlrike Weyer-Czernilofsky
Ulrike Weyer-Czernilofsky
RBRosa Baumgartinger
Rosa Baumgartinger
PJPeter Jung
Peter Jung
PSPatrizia Sini
Patrizia Sini
P53 is known as the guardian of the genome and is one of the most important tumor suppressors. It is inactivated in most tumors, either via tumor protein p53 (TP53) gene mutation or copy number amplification of key negative regulators, e.g., mouse double minute 2 (MDM2). Compounds that bind to the MDM2 protein and disrupt its interaction with p53 restore p53 tumor suppressor activity, thereby promoting cell cycle arrest and apoptosis. Previous clinical experience with MDM2–p53 protein–protein interaction antagonists (MDM2–p53 antagonists) has demonstrated that thrombocytopenia and neutropenia represent on-target dose-limiting toxicities that might restrict their therapeutic utility. Dosing less frequently, while maintaining efficacious exposure, represents an approach to mitigate toxicity and improve the therapeutic window of MDM2–p53 antagonists. However, to achieve this, a molecule possessing excellent potency and ideal pharmacokinetic properties is required. Here, we present the discovery and characterization of brigimadlin (BI 907828), a novel, investigational spiro-oxindole MDM2–p53 antagonist. Brigimadlin exhibited high bioavailability and exposure, as well as dose-linear pharmacokinetics in preclinical models. Brigimadlin treatment restored p53 activity and led to apoptosis induction in preclinical models of TP53 wild-type, MDM2-amplified cancer. Oral administration of brigimadlin in an intermittent dosing schedule induced potent tumor growth inhibition in several TP53 wild-type, MDM2-amplified xenograft models. Exploratory clinical pharmacokinetic studies (NCT03449381) showed high systemic exposure and a long plasma elimination half-life in patients with cancer who received oral brigimadlin. These findings support the continued clinical evaluation of brigimadlin in patients with MDM2-amplified cancers, such as dedifferentiated liposarcoma.



3 December 2024
Verified
Other
Open access
AGAndreas Gollner
Andreas Gollner
DRDorothea Rudolph
Dorothea Rudolph
UWUlrike Weyer-Czernilofsky
Ulrike Weyer-Czernilofsky
RBRosa Baumgartinger
Rosa Baumgartinger
PJPeter Jung
Peter Jung
PSPatrizia Sini
Patrizia Sini
In vitro IC50 (AlphaScreen and CTG cell viability assay) of BI-0252, BI-0282, and brigimadlin

3 December 2024
Verified
Other
Open access
AGAndreas Gollner
Andreas Gollner
DRDorothea Rudolph
Dorothea Rudolph
UWUlrike Weyer-Czernilofsky
Ulrike Weyer-Czernilofsky
RBRosa Baumgartinger
Rosa Baumgartinger
PJPeter Jung
Peter Jung
PSPatrizia Sini
Patrizia Sini
Antibodies used for Western blot analysis.

3 December 2024
Verified
Other
Open access
AGAndreas Gollner
Andreas Gollner
DRDorothea Rudolph
Dorothea Rudolph
UWUlrike Weyer-Czernilofsky
Ulrike Weyer-Czernilofsky
RBRosa Baumgartinger
Rosa Baumgartinger
PJPeter Jung
Peter Jung
PSPatrizia Sini
Patrizia Sini
In vitro activity of MDM2–p53 antagonists brigimadlin, alrizomadlin and milademetan in MDM2-amplified cell lines and MDM2 non-amplified cell lines.